Morepen Laboratories Statistics
Total Valuation
Morepen Laboratories has a market cap or net worth of INR 51.89 billion. The enterprise value is 52.01 billion.
Market Cap | 51.89B |
Enterprise Value | 52.01B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Morepen Laboratories has 547.95 million shares outstanding. The number of shares has increased by 0.24% in one year.
Shares Outstanding | 547.95M |
Shares Change (YoY) | +0.24% |
Shares Change (QoQ) | -2.73% |
Owned by Insiders (%) | 9.36% |
Owned by Institutions (%) | 1.21% |
Float | 302.95M |
Valuation Ratios
The trailing PE ratio is 41.25.
PE Ratio | 41.25 |
Forward PE | n/a |
PS Ratio | 2.76 |
PB Ratio | 5.71 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 44.19 |
EV / Sales | 2.96 |
EV / EBITDA | 28.81 |
EV / EBIT | 31.49 |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | 3.42 |
Debt / EBITDA | 0.16 |
Debt / FCF | n/a |
Interest Coverage | 36.06 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | 12.48% |
Revenue Per Employee | 8.16M |
Profits Per Employee | 546,908 |
Employee Count | 2,152 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +147.84% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +147.84% |
50-Day Moving Average | 66.07 |
200-Day Moving Average | 52.64 |
Relative Strength Index (RSI) | 76.87 |
Average Volume (20 Days) | 3,380,693 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Morepen Laboratories had revenue of INR 17.57 billion and earned 1.18 billion in profits. Earnings per share was 2.30.
Revenue | 17.57B |
Gross Profit | 6.47B |
Operating Income | 1.65B |
Pretax Income | 1.63B |
Net Income | 1.18B |
EBITDA | 1.81B |
EBIT | 1.65B |
Earnings Per Share (EPS) | 2.30 |
Balance Sheet
The company has 169.45 million in cash and 289.99 million in debt, giving a net cash position of -120.54 million or -0.22 per share.
Cash & Cash Equivalents | 169.45M |
Total Debt | 289.99M |
Net Cash | -120.54M |
Net Cash Per Share | -0.22 |
Equity (Book Value) | 8.47B |
Book Value Per Share | 16.57 |
Working Capital | n/a |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 36.84%, with operating and profit margins of 9.40% and 6.70%.
Gross Margin | 36.84% |
Operating Margin | 9.40% |
Pretax Margin | 9.28% |
Profit Margin | 6.70% |
EBITDA Margin | 10.27% |
EBIT Margin | 9.40% |
FCF Margin | n/a |
Dividends & Yields
Morepen Laboratories does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.24% |
Shareholder Yield | -0.24% |
Earnings Yield | 2.42% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |